IPSEN (IPSEY) Projected to Release Earnings on Thursday

IPSEN (OTCMKTS:IPSEY) will likely be issuing its resultson Thursday, July 30th. Analysts expect IPSEN to post earnings of $1.86 per share and revenue of $2.4202 billion for the quarter.

IPSEN Price Performance

IPSEY stock opened at $44.81 on Tuesday. IPSEN has a 12 month low of $30.05 and a 12 month high of $51.10. The firm’s 50-day moving average is $46.12 and its 200 day moving average is $45.30.

Analyst Upgrades and Downgrades

A number of brokerages have commented on IPSEY. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, IPSEN currently has a consensus rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).